January 3, 2013
~ Following US IND approval, Phase I trial to assess safety, tolerability and pharmacokinetics of KU-046 in healthy young volunteers ~
Kareus Therapeutics SA ("Kareus" or the "Company"), the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
The Phase I clinical trial is a randomised, double-blind, placebo-controlled two-part study to assess the safety, tolerability and pharmacokinetics of single ascending oral doses and of multiple ascending oral doses of KU-046 in 54 healthy young volunteers. The study is being conducted by Quintiles, the world's leading biopharmaceutical service provider, at its Phase I Unit at
Kareus has developed a pipeline of novel molecules targeting diseases of the central nervous system based on its proprietary KARLECT chemistry and drug discovery platforms which target dysfunctional energy production in neurons. KU-046 targets bioenergetics pathways upstream from the increased abeta peptide production found in Alzheimer's disease. It has demonstrated significant improvement in cognition in a number of pre-clinical models.
Commenting on the news, Patrick Doyle,
Business and Corporate Development at Kareus Therapeutics, said:
We are excited to have obtained
approval that will bring KU-046 into clinical development. This is a positive milestone, demonstrating the power of Kareus
innovation platform, which has already shown significant improvement in cognition in a number of pre-clinical models.
We now believe we are well positioned to partner KU-046 to take it into the next stages of its development.
Research and Development at Kareus Therapeutics, commented:
Achieving our objective to reach
approval for KU-046 within three
years and in a cost-efficient manner is strong testament to the commitment and hard work of our team.
s disease is the most common form of dementia which affects over 35 million people worldwide and for which there are currently no disease modifying approved treatments. We are therefore hugely excited and encouraged by the potential of KU-046 to treat patients with this devastating condition. The successful discovery of KU-046 has prompted us to use our bioenergetics and KARLECT platforms
to discover drug candidates for other CNS diseases such as Parkinson
s and Huntington
s disease which have similar energy dysfunction
About Kareus Therapeutics SA